GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
August 14 2018 - 8:00AM
Business Wire
- Issued patent expands global patent
portfolio for GlycoMimetics’ late-stage drug candidate targeting
treatment of broad spectrum of patients with acute myeloid leukemia
(AML)
GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company
focused on discovering and developing novel small-molecule drug
candidates to treat rare diseases, announced today that the Japan
Patent Office (JPO) has issued Patent No. 6366150, for uproleselan
(GMI-1271). The newly issued patent covers uproleselan’s
composition of matter as well as pharmaceutical formulations, and
expires in December 2032.
“The JPO’s issuance of a patent for uproleselan extends major
market intellectual property coverage for this E-selectin
antagonist drug candidate,” stated Rachel
King, GlycoMimetics’ Chief Executive Officer. “As the
need for novel AML treatments continues to grow worldwide, the
Japanese patent represents an important component of our
intellectual property portfolio. It protects the composition of
matter of this innovative approach to treating blood cancer.”
As previously announced, the United States Patent and Trademark
Office (USPTO) and European Patent Office have issued patents
directed to the composition of matter of uproleselan,
pharmaceutical formulations of uproleselan, and methods of treating
acute myelogenous leukemia. These patents will also expire in
late-2032. In addition to the above coverage. GlycoMimetics has
ongoing efforts to secure additional patents on uproleselan and its
uses to potentially extend exclusivity beyond 2032.
About Uproleselan (GMI-1271)
Uproleselan is designed to block E-selectin (an adhesion
molecule on cells in the bone marrow) from binding with blood
cancer cells as a targeted approach to disrupting well-established
mechanisms of leukemic cell resistance within the bone marrow
microenvironment. In a Phase 1/2 clinical trial, uproleselan was
evaluated in both newly diagnosed elderly and relapsed/refractory
patients with AML. In both populations, patients treated with
uproleselan together with standard chemotherapy achieved better
than expected remission rates and overall survival compared to
historical controls, which have been derived from results from
third party clinical trials evaluating standard chemotherapy, as
well as lower than expected induction-related mortality rates.
Treatment in these patient populations was generally well
tolerated, with fewer than expected adverse effects. The FDA has
granted uproleselan Breakthrough Therapy designation for the
treatment of adult AML patients with relapsed/refractory (R/R)
disease. GlycoMimetics plans to implement a comprehensive
development program across the clinical spectrum of AML. This will
include a company sponsored Phase 3 trial in R/R AML and two
consortia-sponsored trials in newly diagnosed patients. One
consortium trial will be sponsored by the NCI and will enroll newly
diagnosed patients fit for intensive chemotherapy. The other trial
will be sponsored by the HOVON group in Europe and will enroll
newly diagnosed patients unfit for intensive chemotherapy.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics has
three clinical-stage programs: rivipansel, uproleselan and
GMI-1359. In addition, the company is researching additional
pre-clinical stage compounds based on its specialized chemistry
expertise. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding
the clinical development of the company’s drug candidates,
including the expected timing of completion of clinical trials and
the presentation of clinical data. Actual results may differ
materially from those in these forward-looking statements. For a
further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk
factors described in the company’s annual report on Form 10-K filed
with the U.S. Securities and Exchange Commission (SEC) on March 6,
2018, and other filings GlycoMimetics makes with the SEC from time
to time. Forward-looking statements speak only as of the date of
this release, and GlycoMimetics undertakes no obligation to update
or revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180814005038/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2024 to May 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From May 2023 to May 2024